Extended Valganciclovir Prophylaxis Is Well Tolerated in Pediatric Kidney Transplant Recipients

被引：0
|
作者：
Benchimol, C. [1 ]
Tedesco Silva, H., Jr. [2 ]
Varela-Fascinetto, G. [3 ]
Genevray, M. [4 ]
Bradley, D. [5 ]
Ives, J. [5 ]
机构：
[1] Mt Sinai Med Ctr, New York, NY 10029 USA
[2] Univ Fed Sao Paulo, Sao Paulo, Brazil
[3] Hosp Infantil Mexico Dr Federico Gomez, Mexico City, DF, Mexico
[4] F Hoffmann La Roche, Basel, Switzerland
[5] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2014年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
A342
引用
收藏
页码：497 / 497
页数：1
相关论文
共 50 条
  • [21] Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients
    Hammer, Nathalie
    Hoessly, Linard
    Haidar, Fadi
    Hirzel, Cedric
    de Seigneux, Sophie
    van Delden, Christian
    Vogt, Bruno
    Sidler, Daniel
    Neofytos, Dionysios
    TRANSPLANT INTERNATIONAL, 2024, 37
  • [22] Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis
    Liang, Xinyun
    Famure, Olusegun
    Li, Yanhong
    Kim, S. Joseph
    PROGRESS IN TRANSPLANTATION, 2018, 28 (02) : 124 - 133
  • [23] Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection
    Veceric-Haler, Zeljka
    Bizjak, Bostjan
    Romozi, Karmen
    Arnol, Miha
    CLINICAL NEPHROLOGY, 2017, 88 : S126 - S130
  • [24] EXTENDING VALGANCICLOVIR PROPHYLAXIS IN KIDNEY TRANSPLANT RECIPIENTS IS ASSOCIATED WITH LOWER INCIDENCE OF CYTOMEGALOVIRUS INFECTION
    Bizjak, Bostjan
    Veceric-Haler, Zeljka
    Romozi, Karmen
    Arnol, Miha
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 407 - 407
  • [25] Pharmacokinetics Profile of Valganciclovir in Pediatric Transplant Recipients
    Launay, Elise
    Theoret, Yves
    Litalien, Catherine
    Duval, Michel
    Alvarez, Fernando
    Lapeyraque, Anne-Laure
    Larocque, Diane
    Tapiero, Bruce
    Lamarre, Valerie
    Ovetchkine, Philippe
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 618 - 619
  • [26] PHARMACOKINETIC PROFILE OF VALGANCICLOVIR IN PEDIATRIC TRANSPLANT RECIPIENTS
    Launay, Elise
    Theoret, Yves
    Litalien, Catherine
    Duval, Michel
    Alvarez, Fernando
    Lapeyraque, Anne-Laure
    Phan, Veronique
    Larocque, Diane
    Poirier, Nancy
    Lamarre, Valerie
    Ovetchkine, Philippe
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (04) : 405 - 407
  • [27] Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis
    Paulsen, Grant
    Cumagun, Pia
    Mixon, Emily
    Fowler, Karen
    Feig, Daniel
    Shimamura, Masako
    PEDIATRIC TRANSPLANTATION, 2019, 23 (03)
  • [28] Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis
    Das, Bibhuti B.
    Prusty, Bhupesh K.
    Niu, Jianli
    Sue, Paul K.
    PEDIATRIC TRANSPLANTATION, 2020, 24 (08)
  • [29] Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis
    Helantera, I.
    Kyllonen, L.
    Lautenschlager, I.
    Salmela, K.
    Koskinen, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (09) : 2026 - 2032
  • [30] Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients
    Blanco, Noemie Boillat
    Pascual, Manuel
    Venetz, Jean-Pierre
    Nseir, Ghaleb
    Meylan, Pascal R.
    Manuel, Oriol
    TRANSPLANTATION, 2011, 91 (02) : 251 - 255
12345